Goldman om aktiekurs-nedtur i Novo Nordisk: Vægttabs-pille kan redde meget
23/2 16:53
Uddrag fra Goldman Sachs og Zerohedge Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, “This outcome is the worst-case […]...